Regeneron Pharmaceuticals Inc

REGNNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
608.81 USD
↘ 1.13 (0.19%)🟢PRE MARKET (AS OF 06:36 AM EDT)
🟢Market: OPEN

Regeneron Pharmaceuticals Inc (REGN) trades at $608.81 per share. The technical outlook is "Sell" and the fundamental picture shows "Neutral". Key drivers include a robust Altman Z-Score, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation side, REGN appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Jun 18, 2026.

Open?$607.03
High?$612.50
Low?$600.86
Prev. Close?$609.94
Volume?595
Avg. Volume?1.2M
VWAP?$605.35
Rel. Volume?0.00x
Bid / Ask
Bid?$575.70 × 40
Ask?$638.77 × 40
Spread?$63.07
Midpoint?$607.24
Valuation & Ratios
Market Cap?63.9B
Shares Out?103.0M
Float?98.3M
Float %?94.6%
P/E Ratio?14.46
P/B Ratio?2.03
EPS?$42.19
Dividend?0.59%
Ex-Dividend?N/A
News
Profile
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Themes
Biotech - Drug Development›Immunology & AutoimmuneHealthcare - Oncology›Immunotherapy & Immuno-OncologyHealthcare - Genomics & Precision Medicine›Gene Therapy & Gene Editing
Employees
15.4K
Market Cap
63.9B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.regeneron.com
Listed
1991-04-02
Address
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591
Phone: (914) 847-7000
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
100
Momentum?
45
Short Sent.?
70
Piotroski F-Score?4/9Mixed
Altman Z-Score?6.35Safe
Confidence?66%Moderate
Full Fundamental Analysis →
Short InterestLow
Short % of Float?3.05%Low
Short Interest?3.0M
Days to Cover?2.0
Free Float98.3M
Avg Daily Volume1.5M
Settlement Date2026-05-29
Financial Health
Current Ratio?3.57Strong
Quick Ratio?2.96Strong
Cash Ratio?0.58Adequate
Debt/Equity?0.09Low
ValuationATTRACTIVELY VALUEDvs 10 peers + S&P 500
Score
83/100
P/E?
Peers
100
S&P
83
14.5CHEAP▾
P/B?
Peers
80
S&P
73
2.03CHEAP▾
P/S?
Peers
82
S&P
35
4.29FAIR▾
P/FCF?
Peers
75
S&P
72
15.6CHEAP▾
EV/EBITDA?
Peers
63
S&P
48
15.3FAIR▾
EV/Sales?
Peers
91
S&P
43
4.27FAIR▾
Returns & Efficiency
ROE?
Peers
29
S&P
51
14.1%STRONG▾
ROA?
Peers
63
S&P
77
10.8%STRONG▾
Cash Flow & Enterprise
FCF?$4.1B
Enterprise Value?$63.7B
Fundamentals ratios updated end of day
MarketsMoversWatchlist